Tag: breast cancer drug

Gilead gets Trodelvy FDA priority review for pre-treated HR+/HER2- metastatic breast cancer

businessnewstoday- October 16, 2022

Gilead Sciences said that Trodelvy (sacituzumab govitecan-hziy) has been granted priority review from the US Food and Drug Administration (FDA) for the treatment of another ... Read More

Olema Oncology raises $54m for breast cancer drug candidate OP-1250

pharmanewsdaily- July 23, 2020

Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women's cancers, has raised $54 million in a Series B financing round, which ... Read More

Pharma giants bag Lynparza EMA approval for metastatic breast cancer

pharmanewsdaily- May 19, 2019

Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency's (EMA) approval for their poly ADP-ribose polymerase ... Read More

Genentech gets Kadcyla FDA approval for post-surgery treatment of HER2+ EBC

pharmanewsdaily- May 5, 2019

Kadcyla FDA approval : Roche subsidiary Genentech has secured approval from the US Food and Drug Administration (FDA) for its breast cancer drug Kadcyla (ado-trastuzumab ... Read More

Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men

pharmanewsdaily- April 17, 2019

New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover ... Read More

Abemaciclib FDA approval : Lilly breast cancer drug gets regulatory nod

pharmanewsdaily- September 30, 2017

Abemaciclib FDA approval : Eli Lilly and Company (Lilly) has secured the US FDA approval for Verzenio (abemaciclib) to treat metastatic breast cancer in patients ... Read More

Lilly’s breast cancer drug abemaciclib meets objective in phase 3 trial

pharmanewsdaily- March 22, 2017

Indianapolis-based Lilly has reported that its breast cancer drug, abemaciclib, in combination with fulvestrant, has yielded positive results by meeting its primary endpoint, progression-free survival ... Read More